Literature DB >> 21735081

Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes.

Tomislav Bulum1, Branko Kolarić, Lea Duvnjak, Marko Duvnjak.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has been associated with the insulin resistance. AIMS: To explore the relationship between markers of NAFLD, namely concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALK), γ-glutamyltransferase (GGT), ferritin and bilirubin and insulin resistance in type 1 diabetes.
METHODS: Our study included 353 patients with type 1 diabetes. Insulin sensitivity was measured with estimated glucose disposal rate calculated using the equation: eGDR = 24.31 - (12.22 × WHR) - (3.29 × HT) - (0.57 × HbA1c); WHR = waist to hip ratio, HT = hypertension. Correlations and multiple logistic regressions analysis were performed to identify the relationships between NAFLD associated markers and eGDR, individual components of insulin resistance and risk of insulin resistance.
RESULTS: AST, ALT, AST-to-ALT ratio, ALK and ferritin significantly correlated with insulin resistance measured by eGDR (r = -0.13, -0.14, 0.13, -0.18, and -0.24, respectively; all P < 0.05), and with individual components of insulin resistance, most notably WHR. In a multiple logistic regression model adjusted according to age, sex, duration of diabetes and BMI, increased levels of AST, ALT and ALK resulted in an increased risk for the development of insulin resistance in our subjects (OR = 1.03, 1.02, and 1.01, respectively; all P < 0.05).
CONCLUSIONS: These findings indicate that higher levels of ALT, AST and ALK are additional markers of insulin resistance in type 1 diabetes and suggest that those subjects must be considered as potentially affected not only by a hepatic but also by a multisystemic disease through altered insulin sensitivity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735081     DOI: 10.1007/s10620-011-1807-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  50 in total

1.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese.

Authors:  J B Dixon; P S Bhathal; P E O'Brien
Journal:  Gastroenterology       Date:  2001-07       Impact factor: 22.682

2.  Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Felice Poli; Stefano Rodella; Luca Scala; Roberto Tessari; Luciano Zenari; Giancarlo Falezza
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

Review 3.  Hepatic metabolism of insulin.

Authors:  W C Duckworth; F G Hamel; D E Peavy
Journal:  Am J Med       Date:  1988-11-28       Impact factor: 4.965

4.  Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease.

Authors:  F Angelico; M Del Ben; R Conti; S Francioso; K Feole; S Fiorello; M G Cavallo; B Zalunardo; F Lirussi; C Alessandri; F Violi
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

Review 5.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

6.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

7.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

8.  Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial.

Authors:  Eric S Kilpatrick; Alan S Rigby; Stephen L Atkin
Journal:  Diabetes Care       Date:  2007-03       Impact factor: 19.112

9.  Insulin resistance in insulin-dependent diabetic patients with microalbuminuria.

Authors:  J Yip; M B Mattock; A Morocutti; M Sethi; R Trevisan; G Viberti
Journal:  Lancet       Date:  1993-10-09       Impact factor: 79.321

10.  Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients.

Authors:  H C Pinto; A Baptista; M E Camilo; A Valente; A Saragoça; M C de Moura
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

View more
  11 in total

Review 1.  The interplay of autoimmunity and insulin resistance in type 1 diabetes.

Authors:  Natalie J Nokoff; Marian Rewers; Melanie Cree Green
Journal:  Discov Med       Date:  2012-02       Impact factor: 2.970

2.  Insulin sensitivity modifies the relationship between thyroid function and lipid profile in euthyroid type 1 diabetic patients.

Authors:  Tomislav Bulum; Branko Kolarić; Lea Duvnjak
Journal:  Endocrine       Date:  2012-01-15       Impact factor: 3.633

3.  Associations of Insulin Resistance and Glycemia With Liver Enzymes in Hispanic/Latino Youths: Results From the Hispanic Community Children's Health Study/Study of Latino Youth (SOL Youth).

Authors:  Christina M Parrinello; Bryan J Rudolph; Mariana Lazo; Linda C Gallo; Bharat Thyagarajan; Scott J Cotler; Qibin Qi; Tossaporn Seeherunvong; Denise C Vidot; Howard D Strickler; Robert C Kaplan; Carmen R Isasi
Journal:  J Clin Gastroenterol       Date:  2019-02       Impact factor: 3.062

4.  The effect of low and high plasma levels of insulin-like growth factor-1 (IGF-1) on the morphology of major organs: studies of Laron dwarf and bovine growth hormone transgenic (bGHTg) mice.

Authors:  Katarzyna Piotrowska; Sylwia J Borkowska; Barbara Wiszniewska; Maria Laszczyńska; Sylwia Słuczanowska-Głabowska; Aaron M Havens; John J Kopchick; Andrzej Bartke; Russel S Taichman; Magda Kucia; Mariusz Z Ratajczak
Journal:  Histol Histopathol       Date:  2013-04-24       Impact factor: 2.303

Review 5.  Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease.

Authors:  Kristina Blaslov; Tomislav Bulum; Karin Zibar; Lea Duvnjak
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 6.  Translational approaches: from fatty liver to non-alcoholic steatohepatitis.

Authors:  Natalia Rosso; Norberto C Chavez-Tapia; Claudio Tiribelli; Stefano Bellentani
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 7.  Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease.

Authors:  Neven Baršić; Ivan Lerotić; Lea Smirčić-Duvnjak; Vedran Tomašić; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

Review 8.  Hepatic steatosis in type 1 diabetes.

Authors:  Simon E Regnell; Åke Lernmark
Journal:  Rev Diabet Stud       Date:  2012-02-10

9.  Dietary polyvinyl alcohol and alginate nanofibers ameliorate hyperglycemia by reducing insulin and glucose-metabolizing enzyme levels in rats with streptozotocin-induced diabetes.

Authors:  Muhammad Suryadiningrat; Devia Yoanita Kurniawati; Agung Mujiburrahman; Muhammad Thohawi Elziyad Purnama
Journal:  Vet World       Date:  2021-04-09

10.  Diabetes-induced hepatic pathogenic damage, inflammation, oxidative stress, and insulin resistance was exacerbated in zinc deficient mouse model.

Authors:  Chi Zhang; Xuemian Lu; Yi Tan; Bing Li; Xiao Miao; Litai Jin; Xue Shi; Xiang Zhang; Lining Miao; Xiaokun Li; Lu Cai
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.